Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 277 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Rhinitis Clear all
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917111
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational

Factors That Affect the Development of COPD Symptoms

NCT00740337
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

NCT00296530
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 21, 2026, 5:38 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

NCT03038971
View directory record Official record
Conditions
Allergic Conjunctivitis, Allergic Rhinitis
Interventions
Dose Level 1, Dose Level 2, Placebo
Biological
Lead sponsor
Woodmont Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Results available

Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma

NCT00434421
View directory record Official record
Conditions
Allergy, Asthma
Interventions
Glycerinated German cockroach allergenic extract, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

NCT00132925
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Triamcinolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional

A Study of RhinAer Stylus for Treating Chronic Rhinitis

NCT06599736
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
RhinAer Stylus
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Colorado Springs, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting Phase 4 Interventional

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

NCT04815187
View directory record Official record
Conditions
Meniere Disease, Allergic Rhinitis, Vertigo
Interventions
Montelukast, Placebo
Drug
Lead sponsor
House Ear Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome

NCT01461200
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Swab of vestibule and middle meatus of nose
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 21, 2026, 5:38 AM EDT
Completed No phase listed Observational

Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

NCT00189449
View directory record Official record
Conditions
Allergic Rhinitis, Allergy, Growth
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

NCT01010971
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Azelastine nasal spray
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 21, 2026, 5:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study

NCT06623799
View directory record Official record
Conditions
Mental Health Conditions, Allergic
Interventions
Not listed
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
4 Years to 100 Years
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Neptune City, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 21, 2026, 5:38 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

NCT00247520
View directory record Official record
Conditions
Hay Fever
Interventions
topical nasal rEV131
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2005 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Clinical Equivalence Study of Mometasone Nasal Spray

NCT01850823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
placebo, Mometasone nasal spray
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
25
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Bethesda, Maryland + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years to 5 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2010 · Synced Oct 21, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 21, 2026, 5:38 AM EDT